Product Details: Semaglutide Peptide

Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), designed for laboratory and research purposes. It is chemically stable and of high purity, suitable for in vitro studies and controlled experimental models. [1]

The peptide undergoes independent laboratory verification for composition and purity. Packaging is optimized to prevent chemical degradation during storage and transportation, ensuring reproducible experimental handling. [2]

Mechanism of Action

Semaglutide acts as a GLP-1 receptor agonist, binding specifically to GLP-1 receptors. This receptor engagement initiates intracellular signaling cascades that are central to research studies on receptor-ligand interactions. [3]

Binding of semaglutide triggers cyclic AMP (cAMP) generation and protein kinase activation, which are essential for studies of cellular metabolism and peptide signaling in experimental models. [4]

Structural modifications in semaglutide provide resistance to enzymatic degradation, prolonging peptide stability and maintaining consistent receptor engagement in experimental systems. Its mechanism is limited to receptor-mediated signaling and does not chemically alter surrounding materials, allowing repeated laboratory studies without interference.

Properties of Semaglutide Peptide

• Molecular Formula: C187H291N45O59
• Molecular Weight: 4113.58 g/mol
• CAS Number: 910463-68-2
• PubChem CID: 56843331
• Synonyms: Rybelsus, Wegovy

Research Applications/Benefits

• Facilitates GLP-1 receptor signaling studies in vitro. [4]
• Supports controlled analysis of peptide-receptor interactions. [5]
• Resistant to enzymatic degradation for prolonged experimental activity. [6]
• Provides reproducible results in receptor-mediated signaling experiments. [7]

Why Choose BehemothLabz Semaglutide Peptide?

Choose BehemothLabz, choose quality! We are among the few online sellers that believe in the integrity and purity of products. Our Semaglutide Peptide is designed to meet the industrial criteria and the needs of researchers.Before launching our products, we test them through an independent laboratory to check their purity and ingredients. This procedure maximizes the accuracy and findings of your research experiments.  

Additionally, we deliver nationwide and internationally. We use a secure payment system that safeguards your personal information and prevents unauthorized third-party access.

So, purchase Semaglutide Peptide now and experience quality and purity for your research.

Disclaimer: This information is for educational purposes. We do not allow the human consumption of our products. All our products are sold for laboratory and research experiments. 

References:

1. Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., Strauss, H. M., Gram, D. X., Knudsen, S. M., Nielsen, F. S., Thygesen, P., Reedtz-Runge, S., & Kruse, T. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry, 58(18), 7370–7380. 
2. Giri, T., Sakharwade, S., Subbappa, P., Chinnakadoori, S. R., & Sharma, N. (2025). Regulatory Considerations in Synthetic Peptide Characterization: Techniques and Compliance. Separation Science Plus, 8(6). 
3. Hall, S., Isaacs, D., & Clements, J. N. (2018). Pharmacokinetics and clinical implications of semaglutide: a new Glucagon-Like peptide (GLP)-1 receptor agonist. Clinical Pharmacokinetics, 57(12), 1529–1538.
4. Wang, C., Wu, Z., Zhou, J., Cheng, B., & Huang, Y. (2025). Semaglutide,    glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway. Journal of Cancer Research and Clinical Oncology, 151(3), 103.
5. Leiter, L. A., Bain, S. C., Bhatt, D. L., Buse, J. B., Mazer, C. D., Pratley, R. E., Rasmussen, S., Ripa, M. S., Vrazic, H., & Verma, S. (2020). The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials. Diabetes Obesity and Metabolism, 22(9), 1690–1695. 
6. Bækdal, T. A., Donsmark, M., Hartoft‐Nielsen, M., Søndergaard, F. L., & Connor, A. (2021). Relationship between oral semaglutide tablet erosion and pharmacokinetics: A Pharmacoscintigraphic study. Clinical Pharmacology in Drug Development, 10(5), 453–462. 
7. Huang, R., Xia, H., Meng, T., Fan, Y., Tang, X., Li, Y., Zhang, T., Deng, J., Yao, B., Huang, Y., & Yang, Y. (2025). Construction of human pluripotent stem cell-derived testicular organoids and their use as humanized testis models for evaluating the effects of semaglutide. Theranostics, 15(6), 2597–2623.